Compare ResMed Inc. (RMD) vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 — how do they compare? ResMed Inc. trades at $229.83 (market cap $31.89B), while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $64.82 (market cap $394.18M). The key difference: ResMed Inc. is far larger — about 80.9× Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033's market cap, and ResMed Inc. pays a 1.16% dividend while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 for 63 Days on average.
| RMD | SLVO | |
|---|---|---|
Market Cap | $31.89B | $394.18M |
Volume | 618,314 | 84,843 |
Sector | Health | Income / Options Overlay |
52-Week High | $277.88 | $107.41 |
52-Week Low | $182.82 | $61.81 |
Typical Hold Time | 51 Days | 63 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
SLVO is trading at $63.56, down 2.67% amid bearish technical signals. The stock recently crossed below its 50-day moving average of $73.20, indicating weakening momentum. Recent news highlights silver price declines and technical breakdowns as key drivers. Technical indicators show a bearish moving average signal with neutral oscillators, while RSI levels near 29 suggest potential oversold conditions.
The outlook remains cautious with silver market volatility and dollar strength creating headwinds. Investment opportunity exists if oversold conditions lead to reversal, but risks include continued commodity pressure and technical breakdown. The stock faces resistance at $66-$67 levels with support around $64-$65.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →
